Jerome B. Zeldis, Executive VP of Research & Development at NexImmune, Inc. (NEXI), bought 5,882 shares at $17.00 ($100K) on 2021-02-17, disclosed to the SEC on 2021-02-19.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| NXGL | BUY | 2024-08-27 | $25K | — | Filing → |
| PTCT | SELL | 2024-05-24 | $765K | — | Filing → |
| NXGL | BUY | 2023-05-30 | $12K | — | Filing → |